ISRCTN39268693已完成未知
A randomised prospective trial of CHOP versus MCOP in elderly patients with intermediate and high grade non-Hodgkins lymphoma
Cancer Research UK (CRUK) (UK)0 个研究点目标入组 0 人开始时间: 2001年7月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
- 2003 results in https://doi.org/10.1093/annonc/mdg067 (added 25/01/2019)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Histologically confirmed intermediate and high grade non-Hodgkin's lymphoma classified as: Diffuse centroblastic; Diffuse immunoblastic; B and T-cell lymphoblastic; Peripheral T-cell of mixed or large cell type; Ki-l
- •2. All stages greater than 1a, non bulky
- •3. Age 65 years and over
- •4. Considered fit enough to receive either regimen
- •5. No previous chemotherapy or radiotherapy 6. No previous malignancy, except non-melanoma skin cancer or adequately treated in-situ cervical carcinoma
- •7. No serious concomitant medical condition that would affect short-term progress
- •8. No severe ischaemic heart disease or cardiomyopathy which could make treatment with adriamycin undesirable
排除标准
- •Not provided at time of registration
研究者
相似试验
已完成
不适用
Phase III Trial comparing CHOP to PmitCEBO in Good Risk patients with Histologically Aggressive Non-Hodgkin's Lymphomaymphoma (non-Hodgkin's)Other and unspecified types of non-Hodgkin's lymphomaCancerISRCTN23628366British National Lymphoma Investigation (BNLI) (UK)
招募中
1 期
Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCLDiffuse Large B-Cell LymphomaNCT06760039Sun Yat-sen University112
已完成
不适用
Trial of CHOP versus CIOP in Good Risk Stage II-IV Patients with Histologically Aggressive Non-Hodgkin's Lymphomaymphoma (non-Hodgkin's)Lymphoma (non-Hodgkin's)CancerISRCTN26863825British National Lymphoma Investigation (BNLI) (UK)211
已完成
3 期
Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCLLymphomaNCT00854568Fudan University398
Unknown
3 期
Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell LymphomaPeripheral T-cell LymphomaNCT03952572Peking University244